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This study analyzed the synthesis of Interferon gamma (IFN-γ), Tumor Necrosis Factor
alpha (TNF-α), and Interleukin 10 (IL-10) in chronically infected patients which developed the
symptomatic disease as cerebral or ocular toxoplasmosis. Blood from 61 individuals were
divided into four groups: Cerebral toxoplasmosis/AIDS patients (CT/AIDS group) (n = 15),
ocular toxoplasmosis patients (OT group) (n = 23), chronic toxoplasmosis individuals (CHR
group) (n = 13) and healthy individuals (HI group) (n = 10). OT, CHR, and HI groups
were human immunodeficiency virus (HIV) seronegative. The diagnosis was made by
laboratorial (PCR and ELISA) and clinical subjects. For cytokine determination, peripheral
blood mononuclear cells (PBMC) of each patient were isolated and stimulated in vitro
with T. gondii antigen. IFN-γ, TNF-α, and IL-10 activities were determined by ELISA.
Patients from CT/AIDS and OT groups had low levels of IFN-γ when were compared
with those from CHR group. These data suggest the low resistance to develop ocular
lesions by the low ability to produce IFN-γ against the parasite. The same patients, which
developed ocular or cerebral toxoplasmosis had higher TNF-α levels than CHR individuals.
High TNF-α synthesis contribute to the inflammatory response and damage of the choroid
and retina in OT patients and in AIDS patients caused a high inflammatory response as
the TNF-α synthesis is not affected since monocytes are the major source this cytokine in
response to soluble T. gondii antigens. IL-10 levels were almost similar in CT/AIDS and OT
patients but low when compared with CHR individuals. The deviation to Th2 immune
response including the production of anti-inflammatory cytokines, such as IL-10 may
promote the parasite’s survival causing the tissue immune destruction. IL-10 production in
T. gondii-infected brains may support the persistence of parasites as down-regulating the
intracerebral immune response. All these indicate that OT and CT/AIDS patients produced
low levels of IL-10 (Th2 response) and IFN-γ (Th1 response). They produced high TNF-α
suggesting a high inflammatory response triggered by the parasite.
Keywords: Toxoplasma gondii , cerebral toxoplasmosis and AIDS, ocular toxoplasmosis, cytokines, immune
response
INTRODUCTION
Lifelong infection with the obligate intracellular protozoan
Toxoplasma gondii affects one-third of the human population
globally (Weiss and Dubey, 2009). Although toxoplasmosis is
asymptomatic in themajority of cases,T. gondii infection can have
serious consequences in immunocompromised individuals and in
cases of congenital infection. In the latter case, ocular infection,
posterior retinochoroiditis, is the most frequent clinical mani-
festation of congenital and acquired toxoplasmosis (Delair et al.,
2011; Olariu et al., 2011; Dubey et al., 2012).
The severity and prevalence of the disease vary greatly and is
believed to be affected by the status of the host immune system
(Garweg and Candolfi, 2009), the genotype of infective parasite
strains (Pereira-Chioccola et al., 2009; Dubey et al., 2012), and the
host genetic background (Mack et al., 1999; Sullivan and Jeffers,
2012).
While the physiopathological mechanisms that underlie retinal
damage in ocular toxoplasmosis are yet not fully understood, the
immune response might directly affect the pathogenesis of tox-
oplasmic retinochoroiditis and some cytokines have been shown
to be fundamental to either control or block a protective response
against T. gondii in experimental models (Talabani et al., 2010).
Its importance is even greater in Brazil, where the prevalence
and severity of ocular disease is higher than those reported in
other regions of the world (Gilbert et al., 2008; Ferreira et al.,
2014). In addition, reactivation of the latent infection occurs in
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approximately 30% of immunocompromised patients (Sarciron
and Guerardi, 2000; Robert-Gangneux and Dardé, 2012).
Cerebral toxoplasmosis is the most common AIDS-related
opportunistic infection of the central nervous system and the
most common cause of focal deficits in human immunodefi-
ciency virus (HIV)-positive patients (Pereira-Chioccola et al.,
2009; Vidal and Oliveira, 2013). It has been suggested that
the neurological involvement of HIV leads to an imbalance
of the immune response and, as consequence, the reactiva-
tion of the latent infection occurs (Lin and Bowman, 1992).
However, the understanding of the physiopathology of cerebral
toxoplasmosis remains incomplete.
In immunocompetent individuals, the immune system con-
trols multiplication of the parasites and stops their dissemination.
In addition, it favors the transformation of tachyzoites into brady-
zoites and eventually, the occurrence of tissue cysts. Cytokines
have been shown to play an important role in the pathogenesis
of toxoplasmosis (Costa-Silva et al., 2012a; Ghasemi et al., 2012;
Sullivan and Jeffers, 2012).
Although occur alterations in levels of antibodies and
cytokines during the reactivation of T. gondii infection (Beaman
et al., 1992; Meira et al., 2008, 2011; Hoti and Tandon, 2011),
the role and function of cytokines, in cellular mediation, in
the humoral response, as well as their impaired action in AIDS
patients remain today only partially understood. This study was
aimed to analyze the synthesis of Interferon gamma (IFN-γ),
TumorNecrosis Factor alpha (TNF-α), and Interleukin 10 (IL-10)
in chronically infected patients which developed the symptomatic
disease as cerebral or ocular toxoplasmosis.
MATERIALS AND METHODS
PATIENTS AND SAMPLES
This case-control study was conducted for 17 months (June 2011
to November 2012). We analyzed blood samples from 61 indi-
viduals divided into four groups. Two groups were formed of
chronically patients infected, who developed the symptomatic
disease: The CT/AIDS (cerebral toxoplasmosis and AIDS) group
was composed of clinical samples from 15 patients with cere-
bral toxoplasmosis and AIDS (53% male and 47% female) aged
between 23 and 64 years old. The OT (ocular toxoplasmosis)
group was composed of clinical samples from 23 patients with
ocular toxoplasmosis (57% male and 43% female) aged between
15 and 76 years old. The other two groups, CHR (chronic toxo-
plasmosis individuals) and HI (healthy individuals) were estab-
lished as controls. Clinical samples from 13 chronic individuals
for toxoplasmosis (44% male and 56% female) aged between 25
and 59 years old composed the CHR group. Samples from 10
healthy individuals, seronegative for T. gondii, (Toxoplasma unin-
fected group) (47% male and 53% female) aged between 28 and
38 years old composed the HI group. The OT, CHR, and HI
groups were seronegative for HIV.
The 15 HIV-infected patients were admitted and treated at the
Emilio Ribas Institute of Infectious Diseases, a tertiary teaching
hospital in São Paulo, Brazil. The clinical diagnosis of cerebral
toxoplasmosis in HIV-infected patients was based on: (1) progres-
sive neurological deficits; (2) contrast-enhancing mass lesion(s)
on computed tomography and/or magnetic resonance imaging;
and (3) successful clinical and radiological response to antipara-
sitic treatment within 2 weeks (Portegies et al., 2004; Vidal and
Oliveira, 2013).
OT patients were admitted and treated at the Ophthalmology
Outpatient Clinics from Fundação Faculdade Regional de
Medicina—Hospital de Base, a tertiary teaching hospital in São
José do Rio Preto, São Paulo, Brazil. They were clinically diag-
nosed as having toxoplasmic retinochoroiditis, and the clini-
cal evaluation was performed under fundoscopic examination
using indirect binocular ophthalmoscopy, 20D lens (Binocular
Ophthalmoscope ID 10, Topcon Corporation, USA). The clinical
diagnosis of ocular toxoplasmosis was based on retina visualiza-
tion and the description of the characteristic, the site and the size
of exudative lesions or scars (Mattos et al., 2011; Ferreira et al.,
2014). In order to determine the minimally invasive laboratory
diagnosis, as defined before (Colombo et al., 2005; Mattos et al.,
2011), blood samples fromGroup CT/AIDS andOT patients were
collected before or until the third day of the antiparasitic therapy
for toxoplasmosis.
Ethical considerations
All patients provided written informed consent and the institu-
tional review boards of Ethics Committees of the all Institutions
approved this study.
T. gondii and antigen
T. gondii lysate antigen (TLA) was prepared as described before
(Meira et al., 2008; Costa-Silva et al., 2012b). Tachyzoites (RH
strain) from Vero cell cultures in serum-free medium were puri-
fied by filtration. Then, parasites were washed, suspended in
phosphate-buffered saline (PBS) and lysed using glass beads by
vortex for 8 cycles for 4min with 2-min intervals. Parasite extract
was centrifuged (3000 g) and dissolved in 0.3M NaCl, and the
protein concentration was determined at 280 nm by spectrome-
try in a NanoDrop ND100 (Thermo Scientific). TLA was used
for determination of humoral and cellular response by ELISA.
Tachyzoites were further used for DNA extraction.
SEROLOGICAL DIAGNOSIS
ELISA were performed with microtiter polystyrene plates (flat
bottom, low binding, Corning Incorporated, USA) as previ-
ously described (Meira et al., 2008; Mattos et al., 2011). Briefly,
each well was incubated overnight at 4 C with TLA at a con-
centration of 1μg/ml. The free binding sites were blocked by
treating the wells with 5% skim milk-PBS and after 60min,
50μl each of serum sample (1:200 in 5% skim milk-PBS) were
incubated for 60min at 37◦C. After washes with PBS-Tween
20, the wells were incubated for more 60min at 37◦C with a
horseradish peroxidase-conjugated goat anti-human IgG (Sigma)
and the substrate solution (0.1M citric acid, 0.2M Na2HPO4,
0.05% o-phenylenediamine, 0.1% H2O2) was added to each well.
Color development was stopped by adding 50μl of 4 N H2SO4.
Absorbance values were measured in an ELISA Labsystens-
Multiscan MS Plate Reader (Minneapolis, Minnesota, USA) with
a 492-nm filter. The optical density (O.D.) cutoff was 0.148 at
492-nm wavelength as previously described (Meira et al., 2008).
The absorbance values were subtracted from the background,
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and the arithmetic mean was calculated. O.D. results were trans-
formed in ELISA-relative values (RV) that represent the ratio
of the absorbance of each serum sample at an optical density
of 492 nm to the cutoff value (serum O.D/cutoff O.D.). Values
greater than 1.0 were considered reactive. Low RV was considered
to be between 1 and 5; and high RV, above 6.
MOLECULAR DIAGNOSIS
The DNA of blood samples was extracted by QIAamp DNA Mini
Kit (Qiagen), according to the manufacturer’s instructions. DNA
pellets were dissolved in ultra-pure water. As a positive control,
DNA was extracted from tachyzoite pellets using the same kit.
DNA purity was determined by the ratio of O. D. at 260 and
280 nm in a NanoDrop ND100 (Thermo Scientific). The amplifi-
cations were carried out with a kit purchased from Promega (Go
Taq GreenMaster Mix). The PCRmix (12.5μL) was composed of
1 unit of Taq DNA polymerase, 10mM Tris-HCl, pH 8.5; 50mM
KCl; 1.5mM MgCl2; and 200mM of each dNTP. The reactions
included The PCR mix, 5μL of each DNA template and 25 pmol
of each primer to a final volume of 25μL. The primer pairs used
were B22/B23, which amplified a 115-bp sequence from a spe-
cific repetitive region of B1 gene from T. gondii as target (Burg
et al., 1989). To control the course of extraction and check for
PCR inhibitors, all samples were assayed using β1/β2 (Mesquita
et al., 2010), which amplified a 140 bp fragment of the human
β-globulin gene. Each amplification run contained two negative
controls (ultra-pure water and a negative DNA for toxoplasmo-
sis) and one positive (DNA extracted from tachyzoite pellets). The
thermal cycles and PCR products analyses were made exactly as
described before (Colombo et al., 2005; Mesquita et al., 2010).
ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC)
AND CYTOKINE ASSAYS
About 10ml of blood containing sodium heparin as anticoagulant
collected from all patients and an equal volume of PBS (pH 7.2)
was added to the blood and the peripheral blood mononuclear
cells (PBMC) separated over Histopaque 1077 as per protocol
described by Sigma-Aldrich. After isolation, cells were washed
two times with PBS by centrifugation at 1000 g for 10min
and resuspended in RPMI-1640 medium (Sigma) containing L-
glutamine, 2 g/L sodium bicarbonate, 10% heat-inactivated fetal
calf serum and 50mg/ml of streptomycin. The viability of the cells
used in the experiments was always higher than 85%, as measured
by trypan blue exclusion (Sigma). The cells were then plated at a
density of 1 × 106 cells per well into 48-well culture plates in a
final volume of 500μL.
PBMC were then stimulated with 1μg/mL of TLA.
Alternatively, as control for IFN-γ, TNF-α, and IL-10 experi-
ments, cells were stimulated with 2μg/mL of phytohemagglutinin
(PHA). Culture medium was used in all experiments as negative
control wells. PBMC cultures were maintained at 37◦C in a 5%
CO2 atmosphere and supernatants were collected after 24–48 h of
stimulation. The supernatant was analyzed after 24 h for TNF-α
and IL-10, and 48 h for IFN-γ activity.
The cytokine concentrations were determined using the
Ready-Set-Go ELISA kit according to the manufacturer’s instruc-
tions (Ebioscience, San Diego, California). The limit of sensitivity
of the assays was 2 pg/mL for IL-10 and 4 pg/mL for IFN-γ and
TNF-α.
DATA ANALYSIS
The concentration of each cytokine, per group of patients was
determined by median (in pg/mL). The statistical analyses were
made by the non-parametric Mann–Whitney test for compari-
son between different groups in the GraphPad Prism 5.0 software.
p-value < 0.05 was considered to be statistically significant.
RESULTS
The first step was to establish the clinical and laboratory diagno-
sis of the patients from the both groups. As described in Table 1,
the 15 patients fromCT/AIDS group developed focal cerebral tox-
oplasmosis as they had CD4+ lymphocytes counts less than 100
cells/μl of blood. The values ranged from 4 to 84 cells/μl of blood.
In addition, they had positive PCR for T. gondii in blood, high
ELISA-RV in 67% of the patients and low, in 33% of them. Out
of the 23 patients from OT group, the clinical and fundoscopic
Table 1 | Patients with cerebral toxoplasmosis or ocular
toxoplasmosis: clinical and laboratory diagnosis as well as cytokines
levels after PBMC stimulation with T. gondii TLA antigen.
CT Patientsa(n=15) OT patientsa(n= 23)
Data of the sample
collection (m/y)b
10/11–3/12 5/12–8/12
Median age (range) 43 (23–64) 63 (15–76)
Gender 8M – 7F 13M – 10F
Clinical diagnosisc focal CT (100%) Active RtC (14%)d
Active and RtC scar (2%)
RtC scar (84%)
HIV serology Pos (100%) NDe
CD4+ lym countsf
(range)
4–84 ND
Positive PCR in blood
(for T. gondii DNA)
100% (15/15) 48% (11/23)
Anti-T. gondii
antibodies ELISA
(RV)g
Pos (12.8–3.0) Pos (5.7–1.0)
hIFN-γ—median
(range)
71.47 (0–633.24) 155.30 (27.35–2630.29)
hTNF-α—median
(range)
2564.01 (21.12–11253.62) 2352.00
(401.03–11453.71)
hIL10—median
(range)
3011.50 (17.87–726.38) 580.60 (39.15–2656.17)
aCT (cerebral toxoplasmosis), OT (ocular toxoplasmosis).
bDate (month/year) of the collection.
cDiagnosis was defined by clinical, images and laboratory data as described in
Materials and Methods Section.
d Active and retinochoroiditis (RtC) scars in the right and left eyes, respectively.
eNon-determined (ND).
f Number of CD4+ T lymphocytes/μl of blood.
gELISA are expressed in relative values (RV), which represent the ratio of the
absorbance of each serum sample at an optical density of 492 nm to the cutoff
value (serum O.D./cutoff O.D.). Values greater than 1.0 were considered reactive.
hIFN-γ , TNF-α, and IL10 are expressed in in pg/mL. Pos, positive.
www.frontiersin.org October 2014 | Volume 5 | Article 492 | 3
Meira et al. Cytokines in ocular and cerebral toxoplasmosis
examination determined that 2 patients had active lesions, 2 had
both, active lesions and scars; and 19, retinochoroiditis scars. PCR
was positive in 48% the patients. Low ELISA-RV was shown in
96% (Table 1).
The first part of the determinations of the cytokines was con-
ducted in order to set up the conditions for PBMC cultures.
Different TLA and PHA concentrations to stimulation of PBMC
were tested (1, 2, 5, and 10μg/mL) and the supernatants were
tested after 24, 48 and 72 h of stimulation for each cytokine. After
evaluation of these parameters, PBMC from CT/AIDS and OT
patients; CHR and HI individuals were stimulated in vitro with
1μg/mL of TLA as antigen. In parallel, as controls, the same
cells were stimulated with 2μg/mL of PHA and in the absence
of the antigen. There was no proliferation in PBMC cultures in
the absence of T. gondii antigen or PHA (data not shown). Next,
IFN-γ, TNF-α, and IL-10 levels were evaluated by ELISA in the
supernatant of PBMC collected from the four groups of patients.
Median results of IFN-γ, TNF-α, and IL-10 levels after PBMC
stimulation with TLA, per group of patient are shown in Table 1.
Additionally, the median results of the each cytokine stimulated
with PHA (as positive control) and TLA, per group, were analyzed
and they were shown in details in Figure 1.
The IFN-γ data are shown in Figure 1A. PBMC fromCT/AIDS
and OT patients stimulated with PHA produced 840.60 pg/mL
and 2205.00 pg/mL of IFN-γ, respectively. Differently, PBMC
from CHR and HI individuals produced 4534.09 pg/mL and
3339.34 pg/mL, respectively. The differences between the results
of CT/AIDS and CHR groups were statistically significant at p <
0.005.
PBMC from CHR individuals stimulated with TLA produced
high IFN-γ amounts (1198.91 pg/mL). Nevertheless, PBMC from
patients with CT/AIDS and OT produced low IFN-γ amounts
(71.47 pg/mL and 155.30 pg/mL, respectively). PBMC from HI
individuals produced 90.59 pg/mL of IFN-γ. The differences
between results from CHR and CT/AIDS, CHR and HI individ-
uals were statistically significant at p < 0.005, and between CHR
and OT patients at p < 0.0005.
The TNF-α results are shown in Figure 1B. PBMC from indi-
viduals of all groups were able to produce large amounts of
TNF-α using PHA as stimulus. CHR and HI individuals as
well as CT/AIDS and OT patients, produced 4326.93 pg/mL,
2834.21 pg/mL, 8480.00 pg/mL and 9827.76 pg/mL of TNF-α,
respectively. The differences between OT and HI were statisti-
cally significant at p < 0.05. Lower TNF-α level (992.71 pg/mL)
produced from cells collected from CHR were shown when
compared with CT/AIDS and OT patients (2564.54 pg/mL and
2352.52 pg/mL, respectively).
PBMCofHI individuals stimulated with TLA produced 329.60
pg/mL of TNF-α. The differences between the CHR and OT were
statistically significant at p < 0.005 and between CT/AIDS and
HI at p < 0.005, OT and HI at p < 0.005 and CHR and HI at
p < 0.05.
The results of IL-10 levels are shown in Figure 1C. PBMC
of CHR and HI individuals stimulated with PHA produced
3939.00 pg/mL and 5858.09 pg/mL while CT/AIDS and OT
patients were able to produce 207.21 pg/mL and 2246.87 pg/mL,
respectively. The differences between the CT/AIDS, OT and CHR
were statistically significant at p < 0.05 and between CT/AIDS
and HI at p < 0.005. In OT and HI groups the differences was
at p < 0.05.
No differences in IL-10 levels were observed between PBMC
collected from CHR individuals and CT/AIDS or OT patients
(466.80 pg/mL, 311.50 pg/mL and 580.60 pg/mL, respectively).
However, HI individuals produced high levels (3619.10 pg/mL).
The differences between HI and CT/AIDS, HI and OT or HI and
CHR were statistically significant at p < 0.0005.
DISCUSSION
This study evaluated the cellular response in PBMC samples from
patients with cerebral toxoplasmosis and AIDS and patients with
ocular toxoplasmosis using a TLA (Meira et al., 2013).
The clinical and laboratorial characteristics from the 38
chronically infected patients studied confirmed previous studies
(Colombo et al., 2005; Mattos et al., 2011; Meira et al., 2013). The
15 patients from CT/AIDS group developed focal cerebral tox-
oplasmosis since they had low CD4+ lymphocytes counts. All
patients had tachyzoites in blood since they had positive PCR.
The T. gondii antigens produced high antibody production deter-
mined by ELISA-RV. The other group, which was composed of 23
patients with active lesions or retinochoroiditis scars, was a quite
different. PCR results were positive in almost half of the patients
but they had low ELISA-RV. No differences in IL-10 levels were
observed between PBMC collected from CHR individuals.
The quality of the cells of all groups of individuals was in good
conditions as showed in the PBMC stimulation with PHA. The
importance of IFN-γ to resistance against T. gondii infection has
been demonstrated, as this cytokine is responsible for regulation
of T. gondii load and distribution in the eyes; essential mediator
of the immune response to control T. gondii in the brain and to
maintain the latency of chronic infection (Carruthers and Suzuki,
2007; Gaddi and Yap, 2007; Goldszmid et al., 2012; Nijhawan
et al., 2013). However, patients develop cerebral toxoplasmosis
after reactivation of latent infection during immunosuppression.
In this study these patients (CT/AIDS group) had low levels of
IFN-γwhenwere compared with those fromCHR group (chronic
infected individuals). The patients with ocular toxoplasmosis also
had low levels of IFN-γ and confirm other studies that also
shown IFN-γ levels were elevated in asymptomatic individuals
compared with patients with acquired toxoplasmosis (Yamamoto
et al., 2000; de-la-Torre et al., 2013). These data suggest that resis-
tance or not to develop ocular lesions is associated with the ability
to produce IFN-γ against the parasite. These data, yet, can be cor-
related with recent reported studies that severe ocular infections
in South America due to highly variable T. gondii strains and char-
acterized by a completely different immune response pattern and
much higher ocular parasite loads (de-la-Torre et al., 2013, 2014;
Pfaff et al., 2014). The high levels of this cytokine found in CHR
individuals can be explained by its release by parasite-specific
T lymphocytes, which are required to prevent cyst reactivation
during chronic infection (Sarciron and Guerardi, 2000).
On the other hand, the same patients, which devel-
oped ocular or cerebral toxoplasmosis had higher TNF-α
levels than CHR individuals. This proinflammatory cytokine
is directly involved in the regulation of tachyzoite growth.
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FIGURE 1 | Cytokine production from PBMC after PHA and TLA
stimulation in vitro. PBMC (1 × 106/well) from cerebral toxoplasmosis/AIDS
patients (gray columns), ocular toxoplasmosis (black columns), chronic (white
columns), and healthy individuals (dotted columns) stimulated with 2 and
1μg/mL of PHA and TLA, respectively. Supernatants were collected after
48 h for IFN-γ (A) and 24 h for TNF-α (B) and IL-10 (C). The cytokine levels
were determined by ELISA. The horizontal line indicates the median, bars the
25 and 75% percentiles, and vertical lines the 10 and 90% percentiles.
Comparison of reactivity between groups by Mann–Whitney test (95%
confidence interval) at ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005.
In addition, the balance between IFN-γ and TNF-α is
the key mediators in triggering effector functions against
T. gondii during both acute and chronic stages of infection
(Denkers and Gazzinelli, 1998).
PBMC of OT patients also produced high TNF-α level after
stimulus with TLA. These data are in agreement with other
studies when suggested the susceptibility of OT patients with
the production of TNF-α that contribute to the inflammatory
response and damage of the choroid and retina (Wallace and
Stanford, 2008; Talabani et al., 2010).
In AIDS patients, the TNF-α synthesis is not affected since
monocytes are the major source this cytokine in response to
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soluble T. gondii antigens (Sarciron and Guerardi, 2000). These
findings are in agreement with our data, as we found high levels
TNF-α in CT/AIDS patients suggesting a high inflammatory
response.
IL-10 levels in response to TLA were almost similar in
CT/AIDS and OT patients but low when compared with CHR
individuals. Similar results have been shown by others (Vallochi
et al., 2002; de-la-Torre et al., 2014) and support the idea that
IL-10 seems to be central to the induction of the permissive
state seen in the eyes of South American OT patients (de-la-
Torre et al., 2014). These data, also, could be explained by the
deviation to Th2 immune response including the production
of anti-inflammatory cytokines, such as IL-10, TGF-β, and IL-4
favor the parasite’s survival. This strategy is required to maintain
immune equilibrium in the eye preventing the tissue immune
destruction (Neyer et al., 1997; Gaddi and Yap, 2007). IL-10
production in T. gondii-infected brains may support the persis-
tence of parasites as down-regulating the intracerebral immune
response. The ratio of IFN-γ/IL-10 response in the CHR and
HI groups is related to the immunoregulatory effect as a mixed
Th1/Th2 profile since these individuals have no impairment of
lymphocytes and IFN-γ, which is a key cytokine for the control of
infection (Neyer et al., 1997; Kumar et al., 1998). Similar data have
been shown in chronic infected mice (Costa-Silva et al., 2012a).
All these data together indicate that OT and CT/AIDS patients
produced low IL-10 (Th2 response) and IFN-γ (Th1 response).
In addition, they produced high TNF-α suggesting a high inflam-
matory response triggered by the parasite. IFN-γ levels found in
these patients may be due a global decrease of CD4+ T cells in
CT/AIDS and a possible central tolerance to parasite antigens in
those patients with ocular toxoplasmosis. These particular char-
acteristics in Brazilian patients may be due to the nature of the
infecting South American strains that have shown more severe
those from other regions (Ajzenberg et al., 2004; Ferreira et al.,
2011) or to the genetic susceptibility of the host or by both
combined events.
The monitoring of the immune response to antigens involved
in the different clinical forms of infection can provide valuable
information that can help in understanding the mechanisms of
immune system control over parasites.
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